Researchers used computer modeling to compare immediate versus delayed (2-year) treatment with sotatercept, a new pulmonary arterial hypertension medication, to predict lifetime outcomes.
Study Method: Building on the findings of the phase 3 STELLAR trial on sotatercept the authors of the study refer to a population health model which was recently published assessing the long-term clinical impact of sotatercept. Their analysis expands on this model and compares the clinical outcomes of immediate treatment initiation with sotatercept plus background therapy against delayed treatment initiation with sotatercept plus background therapyusing a six-state Markov-type model and over a lifetime horizon.
Key Results
- Survival Impact: Immediate treatment led to 16.5 years average life expectancy versus 12.4 years with delayed treatment – a 4.1-year difference
- Healthcare Benefits: Per 1,000 patients, immediate treatment prevented 210 hospitalizations and 5 lung/heart-lung transplants
- Quality of Life: Patients gained more years without needing continuous IV prostacyclin therapy
Conclusions
Even a two-year delay in starting sotatercept could cost pulmonary arterial hypertension patients several years of life and result in more hospitalizations and need for transplants. The modeling suggests early treatment initiation is critical, though real-world data is needed to confirm these projections.
Read more at this link on Springer Nature.
Citation
lsumali, A., McLaughlin, V., Chevure, J. et al. Long-Term Mortality and Morbidity Impact on Patients with Pulmonary Arterial Hypertension (PAH) If Access to Sotatercept Is Delayed: A Simulation Model. Adv Ther (2025). https://doi.org/10.1007/s12325-025-03241-4, Received14 March 2025, Accepted 09 May 2025, Published17 June 2025, DOI https://doi.org/10.1007/s12325-025-03241-4